Research Topics
| Barbara CastelnuovoSummaryCountry: Uganda Publications
| Collaborators
|
Detail Information
Publications
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapyMoses R Kamya
Department of Medicine, Makerere University, Kampala, Uganda
J Acquir Immune Defic Syndr 46:187-93. 2007..We identified predictors of viral failure and documented genotypic mutations in a subset of patients with viral failure after 12 months on antiretroviral therapy (ART)...
Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia?Barbara Castelnuovo
Infectious Diseases Institute, Kampala, Uganda
Afr Health Sci 8:133-4. 2008..In resource limited settings patients on antiretroviral treatment who develop stavudine induced hyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative...- Implementation of provider-based electronic medical records and improvement of the quality of data in a large HIV program in Sub-Saharan AfricaBarbara Castelnuovo
Infectious Diseases Institute, Makerere College of Health Sciences, Kampala, Uganda
PLoS ONE 7:e51631. 2012..The objective of this study was to compare the rate of errors in the database before and after the introduction of the provider-based EMR... - Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in UgandaJoseph B Babigumira
Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
BMC Health Serv Res 9:192. 2009..We estimated the potential impact of task-shifting on costs of antiretroviral therapy (ART) and physician supply in Uganda. The study was performed at the Infectious Diseases Institute (IDI) clinic, a large urban HIV clinic... - A review of compliance to anti tuberculosis treatment and risk factors for defaulting treatment in Sub Saharan AfricaB Castelnuovo
Infectious Diseases Institute, Mulago Hospital, Kampala, Uganda
Afr Health Sci 10:320-4. 2010..The aim of this study is to assess anti TB treatment compliance and the factors predictive for poor adherence in Sub-Saharan Africa in the last 10 years... 
Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in UgandaBarbara Castelnuovo
Research Department, Infectious Diseases Institute, Makerere University, Kampala Uganda
J Acquir Immune Defic Syndr 56:59-63. 2011..In resource-limited settings, there are only a few antiretroviral treatment (ART) options. Our objective was to evaluate the reasons for first-line ART changes in resource-limited settings...- Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohortBarbara Castelnuovo
Infectious Diseases Institute, Kampala, Uganda
Clin Infect Dis 49:965-72. 2009.... - Improvement of the patient flow in a large urban clinic with high HIV seroprevalence in Kampala, UgandaB Castelnuovo
Infectious Diseases Institute, PO Box 22418 Mulago Hill, Kampala, Uganda
Int J STD AIDS 20:123-4. 2009..A similar methodology could be used by other health services to evaluate and compare different models of care... - Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicityBarbara Castelnuovo
Infectious Diseases Institute, Kampala, Uganda
J Int Assoc Physicians AIDS Care (Chic) 8:52-9. 2009..To evaluate the safety and virological response to lopinavir/ritonavir containing second-line therapy after failing a first line nonnucleoside reverse transcriptase inhibitor (NNRTI) based regimen... - Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda)Patricia Mwebaze Songa
Infectious Diseases Institute, Makerere University, Kampala, Uganda
Clin Infect Dis 45:514-7. 2007..The median serum lactate level was 6.6 mmol/L. All patients had their antiretroviral treatment regimen discontinued. Hospital admission was required for 5 patients. Five patients died... - Sexual behaviors over a 3-year period among individuals with advanced HIV/AIDS receiving antiretroviral therapy in an urban HIV clinic in Kampala, UgandaBonnie Wandera
Infectious Diseases Institute, Kampala, Uganda
J Acquir Immune Defic Syndr 57:62-8. 2011..Few studies have prospectively examined sexual behaviors of HIV-infected person on antiretroviral therapy (ART) in sub-Saharan Africa... - Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome?Barbara Castelnuovo
Infectious Diseases Institute, Kampala, Uganda
AIDS 22:269-73. 2008..A pruritic papular eruption (PPE) is a common skin manifestation observed in 12-46% of persons with HIV infection living in tropical countries... - Regional differences in predictive accuracy of WHO immunologic failure criteriaAgnes N Kiragga
College of Health Sciences, Infectious Diseases Institute, Uganda
AIDS 26:768-70. 2012..Population-specific guidelines should be developed using large African cohorts to identify more specific and sensitive criteria... - Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in UgandaSabine M Hermans
Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
J Acquir Immune Defic Syndr 60:e29-35. 2012..In December 2008, a separate outdoor-integrated TB/HIV clinic was instituted for attendees of a large urban HIV clinic in Uganda. We sought to evaluate associated TB and HIV treatment outcomes... - Low prevalence of Plasmodium falciparum antigenaemia among asymptomatic HAART-treated adults in an urban cohort in UgandaDamalie Nakanjako
Department of Medicine, Makerere University School of Medicine, Kampala, Uganda
Malar J 10:66. 2011..There is need to evaluate the use of RDTs among highly active anti-retroviral therapy (HAART)-treated people living with HIV (PLHIV)... - Are the best antiretrovirals being used in Africa?Laurence John
Infectious Disease Institute, Mulago Hospital Complex, Kampala, Uganda
J HIV Ther 11:11-5. 2006 - Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settingsDavid B Meya
Infectious Disease Institute, Makerere University, Mulago Hospital Complex, Kampala, Uganda
Clin Infect Dis 51:448-55. 2010..We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify persons with subclinical cryptococcosis and the efficacy of preemptive fluconazole therapy... - Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause?Hasan M Shihab
Infectious Diseases Institute, Makerere University, Kampala, Uganda
J Infect Dev Ctries 3:405-7. 2009..The lack of an alternate explanation led us to suspect that Lopinavir/Ritonavir was potentially responsible for the edema... - Belief in divine healing can be a barrier to antiretroviral therapy adherence in UgandaJane Wanyama
Infectious Disease Institute, Kampala, Uganda
AIDS 21:1486-7. 2007.... - A randomized controlled trial to evaluate the effectiveness of a board game on patients' knowledge uptake of HIV and sexually transmitted diseases at the Infectious Diseases Institute, Kampala, UgandaJane N Wanyama
Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
J Acquir Immune Defic Syndr 59:253-8. 2012..The object of this study was to assess the effect of this educational board game on the uptake of knowledge... - Free antiretrovirals must not be restricted only to treatment-naive patients. Experience in Uganda suggests that restricting access is not the way forwardRobert Colebunders
Infectious Diseases Institute, Faculty of Medicine, Makerere University, Kampala, Uganda
PLoS Med 2:e276. 2005 - Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysisYukari C Manabe
Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
PLoS ONE 7:e39187. 2012..We compared the impact of a continuation phase using 6HE or 4HR on total cost and expected mortality from the perspective of the Ugandan national health system... - Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in UgandaJoseph Sempa
Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda
BMC Public Health 12:736. 2012..This analysis evaluates the cost-effectiveness of initiating cART at a CD4 count between 250-350 cell/μl (early) versus <250 cell/μl (delayed)... - Quality of data collection in a large HIV observational clinic database in sub-Saharan Africa: implications for clinical research and audit of careAgnes N Kiragga
Research Department, Infectious Diseases Institute, Kampala, Uganda
J Int AIDS Soc 14:3. 2011..Our objective was to evaluate the completeness and accuracy of recording of key data HIV items in a large routine observational HIV clinic database... - Evaluation of portable point-of-care CD4 counter with high sensitivity for detecting patients eligible for antiretroviral therapyYukari C Manabe
Infectious Diseases Institute, Makerere College of Health Sciences, Kampala, Uganda
PLoS ONE 7:e34319. 2012.... - Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settingsAgnes N Kiragga
Infectious Diseases Institute, Makerere University, Kampala, Uganda
J Int AIDS Soc 13:42. 2010..Most patients are currently initiated on zidovudine-containing regimens, which can induce anaemia. We investigated the risk factors for early severe anaemia in the first six months of ART initiation... - Evaluation of WHO Criteria for Viral Failure in Patients on Antiretroviral Treatment in Resource-Limited SettingsBarbara Castelnuovo
Infectious Diseases Institute, Makerere University, Mulago Hospital Complex, P O Box 22418, Kampala, Uganda
AIDS Res Treat 2011:736938. 2011..1% with high viremia eventually needed to be switched to second line (P = .008). Conclusions. The use of at least one repeat measurement rather than a single VL measurement could avert from 60% to 80% of unnecessary switches...